About axim biotechnologies inc - AXIM
AXIM Biotechnologies, Inc. operates as a biotechnology company, which engages in the development of diagnostic healthcare solutions. Its product categories include Eye Health, SARS-CoV-2, and fentanyl neutralizing antibody test. The company was founded on November 18, 2010 and is headquartered in San Diego, CA.
AXIM At a Glance
AXIM Biotechnologies, Inc.
6191 Cornerstone Court East
San Diego, California 92121
| Phone | 1-858-923-4422 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Other | Net Income | -1,043,084.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
AXIM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -12.801 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.682 |
AXIM Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
AXIM Liquidity
| Current Ratio | 0.001 |
| Quick Ratio | 0.001 |
| Cash Ratio | 0.001 |
AXIM Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -32.986 |
| Return on Equity | N/A |
| Return on Total Capital | 29.126 |
| Return on Invested Capital | N/A |
AXIM Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -217.362 |
| Total Debt to Total Assets | 270.564 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -217.362 |